** Praxis Precision Medicines PRAX.O on Thursday said its experimental movement disorder drug, ulixacaltamide, met the main goals of two late-stage studies for essential tremor, a condition that causes involuntary shaking

** At least 9 analysts raised PT on PRAX

** Separately, late on Thursday, Praxis announced pricing of a $525 mln public offering

TRIAL WIN SHAKES UP THE PRAXIS STORY

** H.C. Wainwright ("buy," PT: $232) says the trial data "came as a big surprise since almost all investors had walked away from ulixacaltamide" after the earlier futility recommendation in February

** Jefferies (PT: $300) says that "the Street was assigning no value to ET", making the results a "complete upside surprise"

** TD Cowen ("buy," PT: $251) says with "no new ET treatments approved in over 50 years," ulixacaltamide is seen as "poised to fulfill a high unmet need"

** Jones Trading ("buy," PT: $441) expects the drug to achieve blockbuster status in 2028 with U.S. risk-unadjusted peak sales conservatively estimated at $12.2 billion in 2032

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))